Dosing underway in BioNTech's Phase 2 trial of mrna-based BNT111 in advanced melanoma

seekingalpha2021-06-18

BioNTech(NASDAQ:BNTX)announcesthat the first patient has been treated in its Phase 2 cancer vaccine trial, evaluating the Company’s BNT111in combination with Libtayo (cemiplimab), being co-developed ...

Source Link
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

  • ongyiren
    2021-06-20
    ongyiren
    Ok
  • Pierroye
    2021-06-18
    Pierroye
    Great. Like and comment pls
  • LWayne
    2021-06-18
    LWayne
    More pls
  • LaiSB
    2021-06-18
    LaiSB
    Soon will up
  • Jack1999
    2021-06-18
    Jack1999
    Pls comment and like
  • Mm101
    2021-06-18
    Mm101
     Nice
Leave a comment
46